Amin Khan - 10 May 2022 Form 4 Insider Report for GreenLight Biosciences Holdings, PBC

Reporting relationship: Chief Scientific Officer
Issuer ticker: N/A
Reported as of: 10 May 2022
Net transaction value: $0
SEC form: 4
Accepted by SEC: 08 Aug 2022, 10:15:11 UTC
Prior SEC filing: 04 Feb 2022
Next SEC filing: 14 Jun 2023
Source filing: View source filing
Reporting owner signature: /s/ David Kennedy, Attorney-in-fact

Key filing fact

Amin Khan filed Form 4 for GreenLight Biosciences Holdings, PBC on 08 Aug 2022.

Key facts

This page summarizes Amin Khan's Form 4 filing for GreenLight Biosciences Holdings, PBC.
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 08 Aug 2022, 10:15.

Change

Previous filing in this sequence was filed on 04 Feb 2022.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

GRNA transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +318,751
Change %
Price: $0.000000
Shares after: 318,751
Date: 10 May 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 318,751
Exercise price: $7.96
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

25% of the shares underlying the option shall vest on the first anniversary of the grant date and the remainder of the shares shall vest in 36 equal monthly installments thereafter.